BACKGROUND: We need to better understand the risk factors and predictors of medication-related weight gain to improve metabolic health of individuals with schizophrenia. This study explores how trajectories of antipsychotic medication (AP) use impact body weight early in the course of schizophrenia. METHODS: We recruited 92 participants with first-episode psychosis (FEP, n = 92) during their first psychiatric hospitalization. We prospectively collected weight, body mass index (BMI), metabolic markers, and exact daily medication exposure during 6-week hospitalization. We quantified the trajectory of AP medication changes and AP polypharmacy using a novel approach based on meta-analytical ranking of medications and tested it as a predictor of weight gain together with traditional risk factors. RESULTS: Most people started treatment with risperidone (n = 57), followed by olanzapine (n = 29). Then, 48% of individuals remained on their first prescribed medication, while 33% of people remained on monotherapy. Almost half of the individuals (39/92) experienced escalation of medications, mostly switch to AP polypharmacy (90%). Only baseline BMI was a predictor of BMI change. Individuals in the top tercile of weight gain, compared to those in the bottom tercile, showed lower follow-up symptoms, a trend for longer prehospitalization antipsychotic treatment, and greater exposure to metabolically problematic medications. CONCLUSIONS: Early in the course of illness, during inpatient treatment, baseline BMI is the strongest and earliest predictor of weight gain on APs and is a better predictor than type of medication, polypharmacy, or medication switches. Baseline BMI predicted weight change over a period of weeks, when other traditional predictors demonstrated a much smaller effect.

3rd Faculty of Medicine Charles University Prague Czech Republic

Department of Psychiatry Dalhousie University Halifax NS Canada

National Institute of Mental Health Klecany Czech Republic

Psychiatric Hospital Bohnice Prague Czech Republic

See more in PubMed

Afzal M, Siddiqi N, Ahmad B, Afsheen N, Aslam F, Ali A, et al. Prevalence of overweight and obesity in people with severe mental illness: systematic review and meta-analysis. Front Endocrinol. 2021;12:769309. doi:10.3389/fendo.2021.769309. PubMed DOI PMC

Annamalai A, Kosir U, Tek C. Prevalence of obesity and diabetes in patients with schizophrenia. World J Diabetes. 2017;8:390. doi:10.4239/wjd.v8.i8.390. PubMed DOI PMC

Correll CU, Solmi M, Croatto G, Schneider LK, Rohani-Montez SC, Fairley L, et al. Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World Psychiatry. 2022;21:248–71. doi:10.1002/wps.20994. PubMed DOI PMC

Bak M, Fransen A, Janssen J, van Os J, Drukker M. Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One. 2014;9:e94112. doi:10.1371/journal.pone.0094112. PubMed DOI PMC

Manu P, Dima L, Shulman M, Vancampfort D, De Hert M, Correll CU. Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management. Acta Psychiatr Scand. 2015;132:97–108. doi:10.1111/acps.12445. PubMed DOI

Bak M, Drukker M, Cortenraad S, Vandenberk E, Guloksuz S. Antipsychotics result in more weight gain in antipsychotic naive patients than in patients after antipsychotic switch and weight gain is irrespective of psychiatric diagnosis: a meta-analysis. PLoS One. 2021;16:e0244944. doi:10.1371/journal.pone.0244944. PubMed DOI PMC

Brecher M, Leong RW, Stening G, Osterling-Koskinen L, Jones AM. Quetiapine and long-term weight change: a comprehensive data review of patients with schizophrenia. J Clin Psychiatry. 2007;68:597–603. doi:10.4088/JCP.v68n0416. PubMed DOI

Bushe CJ, Slooff CJ, Haddad PM, Karagianis JL. Weight change by baseline BMI from three-year observational data: findings from the worldwide schizophrenia outpatient health outcomes database. J Psychopharmacol (Oxf). 2013;27:358–65. doi:10.1177/0269881112473789. PubMed DOI

Gebhardt S, Haberhausen M, Heinzel-Gutenbrunner M, Gebhardt N, Remschmidt H, Krieg J-C, et al. Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course. J Psychiatr Res. 2009;43:620–6. doi:10.1016/j.jpsychires.2008.11.001. PubMed DOI

Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry. 2001;62:92–100. PubMed

Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7:64–77. doi:10.1016/S2215-0366(19)30416-X. PubMed DOI PMC

Vochoskova K, McWhinney SR, Fialova M, Kolenic M, Spaniel M, Svancer P, et al. Weight and metabolic changes in early psychosis―association with daily quantification of medication exposure during the first hospitalization. Acta Psychiatr Scand. 2023;148:265–76. doi:10.1111/acps.13594. PubMed DOI

Farrell C, Brink J. The prevalence and factors associated with antipsychotic polypharmacy in a forensic psychiatric sample. Front Psych. 2020;11:263. doi:10.3389/fpsyt.2020.00263. PubMed DOI PMC

Fleischhacker WW, Uchida H. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. Int J Neuropsychopharmacol. 2014;17:1083–93. doi:10.1017/S1461145712000399. PubMed DOI

Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res. 2012;138:18–28. doi:10.1016/j.schres.2012.03.018. PubMed DOI PMC

Campforts B, Drukker M, Crins J, Van Amelsvoort T, Bak M. Association between antipsychotic medication and clinically relevant weight change: meta-analysis. BJPsych Open. 2023;9:e18. doi:10.1192/bjo.2022.619. PubMed DOI PMC

Siskind D, Gallagher E, Winckel K, Hollingworth S, Kisely S, Firth J, et al. Does switching antipsychotics ameliorate weight gain in patients with severe mental illness? A systematic review and meta-analysis Schizophr Bull. 2021;47:948–58. doi:10.1093/schbul/sbaa191. PubMed DOI PMC

Speyer H, Westergaard C, Albert N, Karlsen M, Stürup AE, Nordentoft M, et al. Reversibility of antipsychotic-induced weight gain: a systematic review and meta-analysis. Front Endocrinol. 2021;12:577919. doi:10.3389/fendo.2021.577919. PubMed DOI PMC

Wang H-H, Cai M, Wang H-N, Chen Y-C, Zhang R-G, Wang Y, et al. An assessor-blinded, randomized comparison of efficacy and tolerability of switching from olanzapine to ziprasidone and the combination of both in schizophrenia spectrum disorders. J Psychiatr Res. 2017;85:59–65. doi:10.1016/j.jpsychires.2016.11.002. PubMed DOI

Kim SH, Ivanova O, Abbasi FA, Lamendola CA, Reaven GM, Glick ID. Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study. J Clin Psychopharmacol. 2007;27:365–8. doi:10.1097/JCP.0b013e3180a9076c. PubMed DOI

Ried LD, Renner BT, Bengtson MA, Wilcox BM, Wilfred WA. Weight change after an atypical antipsychotic switch. Ann Pharmacother. 2003;37:1381–6. doi:10.1345/aph.1C470. PubMed DOI

Lin C-C, Bai Y-M, Wang Y-C, Chen T-T, Lai I-C, Chen J-Y, et al. Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to Amisulpride from other atypical antipsychotics. J Clin Psychopharmacol. 2009;29:529–36. doi:10.1097/JCP.0b013e3181bf613e. PubMed DOI

Montes JM, Rodriguez JL, Balbo E, Sopelana P, Martin E, Soto JA, et al. Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone. Prog Neuro-Psychopharmacol Biol Psychiatry 2007;31:383–8. doi:10.1016/j.pnpbp.2006.10.002. PubMed DOI

Schuster J-P, Raucher-Chéné D, Lemogne C, Rouillon F, Gasquet I, Leguay D, et al. Impact of switching or initiating antipsychotic treatment on body weight during a 6-month follow-up in a cohort of patients with schizophrenia. J Clin Psychopharmacol. 2012;32:672–7. doi:10.1097/JCP.0b013e31826866db. PubMed DOI

Karayal ON, Glue P, Bachinsky M, Stewart M, Chappell P, Kolluri S, et al. Switching from quetiapine to ziprasidone: a sixteen-week, open-label, multicenter study evaluating the effectiveness and safety of ziprasidone in outpatient subjects with schizophrenia or schizoaffective disorder. J Psychiatr Pract. 2011;17:100–9. doi:10.1097/01.pra.0000396061.05269.c8. PubMed DOI

Mitchell AJ, Vancampfort D, De Herdt A, Yu W, De Hert M. Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. Schizophr Bull. 2013;39:295–305. doi:10.1093/schbul/sbs082. PubMed DOI PMC

Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394:939–51. doi:10.1016/S0140-6736(19)31135-3. PubMed DOI PMC

Sabé M, Pallis K, Solmi M, Crippa A, Sentissi O, Kaiser S. Comparative effects of 11 antipsychotics on weight gain and metabolic function in patients with acute schizophrenia: a dose-response meta-analysis. J Clin Psychiatry. 2023;84. doi:10.4088/JCP.22r14490. PubMed DOI

Ratzoni G, Gothelf D, Brand-Gothelf A, Reidman J, Kikinzon L, Gal G, et al. Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry. 2002;41:337–43. doi:10.1097/00004583-200203000-00014. PubMed DOI

Schimmelmann BG, Mehler-Wex C, Lambert M, Schulze-zur-Wiesch C, Koch E, Flechtner HH, et al. A prospective 12-week study of quetiapine in adolescents with schizophrenia spectrum disorders. J Child Adolesc Psychopharmacol. 2007;17:768–78. doi:10.1089/cap.2007.0048. PubMed DOI

Tek C, Kucukgoncu S, Guloksuz S, Woods SW, Srihari VH, Annamalai A. Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications: weight gain in FEP patients. Early Interv Psychiatry. 2016;10:193–202. doi:10.1111/eip.12251. PubMed DOI PMC

Zipursky RB, Gu H, Green AI, Perkins DO, Tohen MF, McEvoy JP, et al. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry. 2005;187:537–43. doi:10.1192/bjp.187.6.537. PubMed DOI

Faries DE, Ascher-Svanum H, Nyhuis AW, Kinon BJ. Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia. Curr Med Res Opin. 2008;24:1399–405. doi:10.1185/030079908X297385. PubMed DOI

Godleski LS, Goldsmith LJ, Vieweg WV, Zettwoch NC, Stikovac DM, Lewis SJ. Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia. J Clin Psychiatry. 2003;64:119–22. doi:10.4088/JCP.v64n0203. PubMed DOI

Ascher-Svanum H, Stensland MD, Kinon BJ, Tollefson GD. Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic. J Psychopharmacol (Oxf). 2005;19:110–7. doi:10.1177/0269881105058978. PubMed DOI

Czobor P, Volavka J, Sheitman B, Lindenmayer J-P, Citrome L, McEvoy J, et al. Antipsychotic-induced weight gain and therapeutic response: a differential association: J Clin Psychopharmacol. 2002;22:244–51. doi:10.1097/00004714-200206000-00003. PubMed DOI

Leadbetter R, Shutty M, Pavalonis D, Vieweg V, Higgins P, Downs M. Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry. 1992;149:68–72. doi:10.1176/ajp.149.1.68. PubMed DOI

Luckhoff H, Phahladira L, Scheffler F, Asmal L, Du Plessis S, Chiliza B, et al. Weight gain and metabolic change as predictors of symptom improvement in first-episode schizophrenia spectrum disorder patients treated over 12 months. Schizophr Res. 2019;206:171–6. doi:10.1016/j.schres.2018.11.031. PubMed DOI

Doporučené postupy psychiatrické péče Psychiatrické společnosti ČLS JEP. https://postupy-pece.psychiatrie.cz/specialni-psychiatrie/f2-schizofrenie/lecba-akutni-epizody-schizofrenie; Published 2018. Accessed January 8, 2024.

National Collaborating Centre for Mental Health (UK) . Psychosis and schizophrenia in adults: Treatment and management: Updated edition 2014. London: National Institute for Health and Care Excellence (UK); 2014. PubMed

Remington G, Addington D, Honer W, Ismail Z, Raedler T, Teehan M. Guidelines for the pharmacotherapy of schizophrenia in adults. Can J Psychiatr. 2017;62:604–16. doi:10.1177/0706743717720448. PubMed DOI PMC

American Psychiatric Association, editor. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. 3rd ed. Washington, DC: American Psychiatric Association; 2021.

Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry. 2016;50:410–72. doi:10.1177/0004867416641195. PubMed DOI

Premier épisode psychotique - Choix de l’antipsychotique. https://www.chuv.ch/fileadmin/sites/dp/documents/dp-uppc-premier-episode-psychotique.pdf; Published 2024. Accessed March 30, 2024.

Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998–2000. J Clin Psychiatry. 2004;65:1377–88. doi:10.4088/JCP.v65n1013. PubMed DOI

Faries D, Ascher-Svanum H, Zhu B, Correll C, Kane J. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry. 2005;5:26. doi:10.1186/1471-244X-5-26. PubMed DOI PMC

Barbui C, Nosè M, Mazzi MA, Thornicroft G, Schene A, Becker T, et al. Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries: Int Clin Psychopharmacol. 2006;21:355–62. doi:10.1097/01.yic.0000224785.68040.43. PubMed DOI

Correll CU, Frederickson AM, Kane JM, Manu P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res. 2007;89:91–100. doi:10.1016/j.schres.2006.08.017. PubMed DOI PMC

Tiihonen J, Taipale H, Mehtälä J, Vattulainen P, Correll CU, Tanskanen A. Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia. JAMA Psychiatry. 2019;76:499. doi:10.1001/jamapsychiatry.2018.4320. PubMed DOI PMC

Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull. 2009;35:443–57. doi:10.1093/schbul/sbn018. PubMed DOI PMC

Taylor M, Cavanagh J, Hodgson R, Tiihonen J. Examining the effectiveness of antipsychotic medication in first-episode psychosis. J Psychopharmacol (Oxf). 2012;26:27–32. doi:10.1177/0269881112439252. PubMed DOI

Crossley NA, Constante M, McGuire P, Power P. Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis. Br J Psychiatry. 2010;196:434–9. doi:10.1192/bjp.bp.109.066217. PubMed DOI PMC

Zhang J-P, Gallego JA, Robinson DG, Malhotra AK, Kane JM, Correll CU. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2013;16:1205–18. doi:10.1017/S1461145712001277. PubMed DOI PMC